HCC

Ghasson K. Abou-Alfa, MD, discusses that phase 2 study of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma.

The indication for nivolumab as a single agent for the treatment of hepatocellular carcinoma in patients previously treated with sorafenib has been withdrawn from the US market.

Sintilimab in combination with the bevacizumab biosimilar, IBI305, is associated with a significant overall survival and progression-free survival benefit over sorafenib in the first-line setting for the treatment of Chinese patients with unresectable, hepatitis B virus-associated hepatocellular carcinoma.

A network meta-analysis looking at 4 studies that assessed atezolizumab/bevacizumab compared to lenvatinib showed there was not a statistically significant improvement for patients with unresectable hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma.

In an interview with Targeted Oncology, HEPANOVA EF-30 investigator, Eleni Gikka, MD, provided insight into the use of TTFields in combination with standard of care therapy for patients with advanced hepatocellular carcinoma.

Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma.

A phase 2 trial of tislelizumab and another trial of Tumor Treating Fields accompanied by sorafenib are filling unmet needs in advanced hepatocellular carcinoma, although more data are still needed in this space.

Patients with unresectable hepatocellular carcinoma with Child-Pugh class B liver function experienced a similar tumor size reduction as their Child-Pugh class A counterparts, all treated with lenvatinib, according to a post-hoc analysis of the phase 3 REFLECT study.

As June is Cancer Immunotherapy Month, Mehmet Akce, MD, discusses the future of immunotherapy in HCC in an interview with Targeted Oncology.

The combination of cabozantinib and atezolizumab demonstrated improvement in both progression-free and overall survival compared with sorafenib, in patients with untreated advanced hepatocellular carcinoma.

New published data from a phase 2/3 trial shows the increased survival benefit of PD-1 inhibitor sintililmab and bevacizumab biosimilar IBI305 in the frontline setting for patients with metastatic HCC.

Ghassan K. Abou-Alfa, MD, MBA, shares clinical pearls and advice for the management of patients with unresectable HCC.

Gastrointestinal oncology expert, Dr Ghassan K. Abou-Alfa, discusses future directions and promising novel approaches under investigation for the treatment of unresectable HCC.

Dr Ghassan K. Abou-Alfa provides insight from the results of the REFLECT trial comparing sorafenib vs lenvatinib in patients with unresectable HCC and comments on the safety profile of lenvatinib.

An expert in gastrointestinal oncology comments on approaching first-line therapy for a patient with previously untreated, unresectable HCC and reviews key findings from the IMbrave150 trial.

Ghassan K. Abou-Alfa, MD, MBA, presents the case of a 68-year-old man with hepatocellular carcinoma (HCC) and shares his initial impressions.

The combination of camrelizumab and apatinib has shown long-term survival benefit in patients with advanced hepatocellular carcinoma, according to updated results from the RESCUE trial.

Richard Finn, MD, professor of Medicine at the Geffen School of Medicine at the University of California Los Angeles, discusses both the recent advances and remaining unmet needs in hepatocellular carcinoma.

An FDA Oncologic Drugs Advisory Committee meeting resulted in continued approval for 4 of 6 indications that were discussed, although all 6 indications did not demonstrate clinical benefit in confirmatory studies. The meeting, held April 27-29, evaluated anti–PD-1/PD-L1 drugs that received accelerated approvals through the FDA’s accelerated approval program, a nearly 30-year-old initiative to expedite the approval process.

An updated analysis, presented at the 2021 ASCO Annual Meeting, showed encouraging signs for the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

Results from the phase 2 LTHAIC study showed that adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib achieved robust and durable responses in patients with advanced hepatocellular carcinoma.

Amit Singal, MD, discusses options after surgical resection for patients with hepatocellular carcinoma.

In an interview with Targeted Oncology, Thomas Marron, MD, PhD, discussed neoadjuvant cemiplimab for the treatment of hepatocellular carcinoma.

Thomas Marron, PhD, MD, discusses the safety and tolerability of neoadjuvant sunitinib in hepatocellular carcinoma.

The FDA’s Oncologic Drug Advisory Committee voted 5 to 4 against the continued accelerated approval of nivolumab for the treatment of patients with hepatocellular carcinoma who were previously treated with sorafenib.

In an 8 to 0 vote, the FDA’s Oncologic Drug Advisory Committee opted to continue to accelerated approval of pembrolizumab for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

In the past 3 years, the FDA has approved 7 novel drugs, either given alone or in combination, to help treat patients with hepatocellular carcinoma.

Michael R. Charlton, MD, MBBS, discusses the impact of the LEGACY trial investigating yttrium-90 radioembolization in patients with solitary, unresectable hepatocellular carcinoma.

Half of all patients with hepatocellular carcinoma treated with the combination of regorafenib and nivolumab following progression on 2 lines of chemotherapy achieved disease control, according to initial results from a phase 2 proof-of-concept trial.